Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$30.03
+0.8%
$30.31
$26.25
$40.49
$15.29B0.614.41 million shs5.60 million shs
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$163.08
-1.4%
$149.53
$93.17
$168.17
$39.48B0.662.24 million shs4.64 million shs
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$116.30
$115.72
$60.03
$116.38
$26.63B1.032.50 million shsN/A
Olympus Co. stock logo
OCPNY
Olympus
$18.00
-1.4%
$18.00
$16.80
$74.99
$23.15B0.7860,265 shs400 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
0.00%-4.83%-5.20%-10.21%-11.58%
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
0.00%+3.16%+6.98%+25.58%+59.00%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00%0.00%0.00%0.00%0.00%
Olympus Co. stock logo
OCPNY
Olympus
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baxter International Inc. stock logo
BAX
Baxter International
4.4283 of 5 stars
2.23.01.74.02.81.72.5
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
4.5795 of 5 stars
2.43.04.23.62.81.71.9
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
1.1402 of 5 stars
0.00.00.03.20.61.71.9
Olympus Co. stock logo
OCPNY
Olympus
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
2.44
Hold$37.2524.06% Upside
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
2.79
Moderate Buy$157.43-3.47% Downside
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00
N/AN/AN/A
Olympus Co. stock logo
OCPNY
Olympus
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OCPNY, CAH, BAX, and HZNP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$166.00 ➝ $181.00
6/13/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$157.00 ➝ $170.00
6/12/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$175.00 ➝ $180.00
6/10/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$165.00 ➝ $170.00
6/3/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$136.00 ➝ $179.00
5/5/2025
Baxter International Inc. stock logo
BAX
Baxter International
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$30.00 ➝ $28.00
5/5/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$142.00 ➝ $166.00
5/2/2025
Baxter International Inc. stock logo
BAX
Baxter International
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$36.00 ➝ $33.00
5/2/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$156.00 ➝ $170.00
5/1/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
4/29/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$150.00 ➝ $160.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$10.64B1.45$4.79 per share6.27$13.76 per share2.18
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$226.83B0.17$10.39 per share15.70($13.19) per share-12.36
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$3.63B7.34$7.05 per share16.49$22.38 per share5.20
Olympus Co. stock logo
OCPNY
Olympus
$7.74B2.99$1.22 per share14.76$3.50 per share5.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
-$649M-$1.10N/A11.000.88-4.71%17.24%5.12%8/5/2025 (Estimated)
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$852M$6.4125.4418.221.850.70%-68.84%4.21%8/13/2025 (Estimated)
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$521.48M$1.8762.1920.553.9612.02%20.46%11.52%N/A
Olympus Co. stock logo
OCPNY
Olympus
$1.03B$0.8221.9520.691.0713.80%24.30%9.30%N/A

Latest OCPNY, CAH, BAX, and HZNP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Baxter International Inc. stock logo
BAX
Baxter International
$0.48$0.62+$0.14$0.25$2.59 billion$2.63 billion
5/1/2025Q3 2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$2.15$2.35+$0.20$2.10$55.33 billion$54.88 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$0.682.26%N/AN/A N/A
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$2.021.24%N/A31.51%29 Years
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/A
Olympus Co. stock logo
OCPNY
Olympus
$0.080.44%N/A9.76%N/A

Latest OCPNY, CAH, BAX, and HZNP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
quarterly$0.51071.35%7/1/20257/1/20257/15/2025
5/6/2025
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.172.27%5/30/20255/30/20257/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.33
2.02
1.40
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
N/A
0.94
0.50
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.48
4.27
4.09
Olympus Co. stock logo
OCPNY
Olympus
0.59
1.99
1.48

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
87.17%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
80.37%
Olympus Co. stock logo
OCPNY
Olympus
0.03%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.21%
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
0.09%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2.20%
Olympus Co. stock logo
OCPNY
Olympus
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
38,000513.17 million512.10 millionOptionable
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
48,900238.68 million238.46 millionOptionable
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2,115228.99 million223.96 millionOptionable
Olympus Co. stock logo
OCPNY
Olympus
31,5571.29 billionN/ANot Optionable

Recent News About These Companies

27 Olympus Way, Lyons ACT 2606
Overwatch 2 Battle for Olympus Event

New MarketBeat Followers Over Time

Media Sentiment Over Time

Baxter International stock logo

Baxter International NYSE:BAX

$30.02 +0.23 (+0.76%)
Closing price 03:59 PM Eastern
Extended Trading
$30.03 +0.01 (+0.02%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Cardinal Health stock logo

Cardinal Health NYSE:CAH

$163.08 -2.32 (-1.40%)
Closing price 03:59 PM Eastern
Extended Trading
$162.92 -0.17 (-0.10%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Horizon Therapeutics Public stock logo

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Olympus stock logo

Olympus OTCMKTS:OCPNY

$18.00 -0.25 (-1.37%)
As of 01/31/2023

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.